Atlas Trials

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Clinical trial NCT05490771 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05490771
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphatic System NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
Start date
2018-06-20
Primary completion
2021-01-06
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.